FAST, Fellows and CARB-X Update January 2020
Fast & Fellows Round-Up
- Fauna Bio (FAST Spring ’19) and announced they have entered into a research collaboration with Novo Nordisk to discover novel therapeutics for obesity Read More
- CellFe (FAST Fall ’18) announced they had raised $3.6 million in a seed round co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures Read More
- Inflammatix (FAST Fall ’17) announced a $32 million Series C financing Read More
- Pheronym’s (FAST Fall ’17) nematodes successfully launched into space for its first-ever agricultural bio-control experiment on the International Space Station (ISS) Read More
- Phi Therapeutics (FAST Fall ’17) raised a $1.5 million seed round Read More
- Shasqi (FAST Spring ’16) featured in San Francisco Business Times article: How a small biotech worked its way out of storage space during the industry’s biggest conference Read More
- Fellows member NuMedii announced a pharmaceutical discovery collaboration with a drug delivery company to develop new therapeutics for ulcerative colitis Read More
CARB-X News
- CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea Read More
- CARB-X funds Vedanta Biosciences to accelerate the development of a new category of oral therapeutics to help a patient’s microbiota fight drug-resistant bacteria Read More
- CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria Read More
- CARB-X funds TAXIS Pharmaceuticals to accelerate development of innovative efflux pump inhibitors (EPIs), a new drug class that would impair bacteria’s ability to fight antibiotics Read More
- CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them Read More